+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
23-Valent Pneumococcal Polysaccharide Vaccine Market - Global Forecast 2026-2032- Product Image
23-Valent Pneumococcal Polysaccharide Vaccine Market - Global Forecast 2026-2032- Product Image
Sale

23-Valent Pneumococcal Polysaccharide Vaccine Market - Global Forecast 2026-2032

  • Report

  • 198 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6277102
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The 23-Valent Pneumococcal Polysaccharide Vaccine Market is projected to reach USD 1.13 Billion in 2026. It is expected to continue growing at a CAGR of 7.72%, reaching USD 1.77 Billion by 2032.

Introduction: The Role of 23-Valent Pneumococcal Polysaccharide Vaccination

The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is designed to protect against invasive disease and pneumonia associated with 23 Streptococcus pneumoniae serotypes. Its use is shaped by age, underlying medical conditions, prior vaccination, national immunization policy, and recommendations from public-health authorities. Because protection and scheduling requirements differ across populations, effective deployment depends on clinically appropriate patient assessment and alignment with local guidance.

Transformative Shifts in Pneumococcal Prevention and Delivery

Pneumococcal prevention is shifting toward risk-based vaccination pathways that distinguish older adults from people with immunocompromising conditions, chronic diseases, or other elevated risks. Many jurisdictions increasingly evaluate PPSV23 alongside pneumococcal conjugate vaccines, with product sequence and timing determined by national recommendations. Delivery is also being influenced by routine adult immunization, pharmacy-based services, electronic reminders, strengthened procurement systems, and efforts to improve access among underserved populations.

How Artificial Intelligence Is Influencing Pneumococcal Vaccination

Artificial intelligence can support pneumococcal vaccination programs by identifying patients who may be eligible from electronic health records, reconciling prior immunization histories, and prioritizing outreach according to age and clinical risk. Analytics may also help public-health teams identify geographic or demographic gaps, improve appointment planning, and monitor safety signals. These applications require validated clinical rules, representative data, privacy safeguards, human oversight, and clear separation between decision support and prescribing or administration decisions.

Regional Insights Across Six Public-Health Environments

North America generally benefits from established adult immunization guidance, broad healthcare infrastructure, and multiple vaccination channels, while access and uptake can still vary by insurance status, geography, and trust. Europe combines strong public-health capacity with differing national schedules, reimbursement arrangements, and recommendations across countries. Asia-Pacific includes mature immunization systems alongside rapidly expanding healthcare access, creating varied implementation needs. Latin America continues to strengthen adult and risk-based vaccination while addressing affordability, primary-care reach, and supply continuity. The Middle East shows substantial variation in policy, healthcare capacity, and expatriate populations. Africa’s priorities include improving adult-risk identification, cold-chain and primary-care capacity, financing, and awareness, particularly for people with comorbidities and those living with HIV.

Group Insights: ASEAN, BRICS, EU, G7, GCC, and NATO

ASEAN members face diverse health-system capabilities and national recommendations, making regional coordination, reliable procurement, and adult-risk communication especially important. BRICS countries span large and varied populations, with opportunities to strengthen surveillance, domestic production capabilities, and equitable access while adapting policies to local disease burdens. The European Union benefits from coordinated scientific and regulatory structures, but vaccination schedules and funding decisions remain primarily national. G7 systems typically have stronger adult immunization infrastructure and data capacity, with persistent challenges in reaching hesitant or medically underserved groups. GCC countries can leverage centralized procurement and modern healthcare networks, while NATO members may place additional emphasis on continuity of essential health services and protection of medically vulnerable populations during emergencies.

Country Insights: Policy and Delivery Considerations

Australia, Canada, France, Germany, Italy, Japan, Spain, the United Kingdom, and the United States have established vaccination systems, but eligibility criteria, sequencing with conjugate vaccines, funding, and delivery settings differ by jurisdiction. Brazil, China, India, Mexico, Russia, and South Korea combine substantial healthcare capabilities with regional variation in access, surveillance, and adult immunization implementation. Across these countries, practical priorities include maintaining accurate vaccination records, integrating recommendations into primary care, improving outreach to older adults and high-risk patients, and ensuring consistent product availability. National decisions should follow current guidance from the relevant health authorities rather than assuming that practices are transferable across borders.

Actionable Priorities for Industry and Public-Health Leaders

Leaders should align product education, clinical decision support, and patient communications with current national recommendations, especially where PPSV23 is used within a broader pneumococcal vaccination sequence. Strengthening partnerships with primary-care practices, pharmacies, hospitals, and community organizations can improve identification and reach of eligible adults. Investments in interoperable immunization records, reminder systems, workforce training, and transparent safety communication can reduce missed opportunities. Procurement planning should include supply resilience, equitable allocation, appropriate storage, and monitoring of administration data, while evaluation should focus on coverage among priority groups and reduction of preventable disease rather than volume alone.

Research Methodology: Evidence-Based Executive Synthesis

This executive summary uses the supplied market definition-23-valent pneumococcal polysaccharide vaccine-and synthesizes established public-health and clinical considerations without introducing market estimates, forecasts, shares, or company-specific claims. The analysis is structured around vaccine use, policy evolution, healthcare delivery, digital tools, geography, population groupings, and country implementation. Interpretations should be validated against current guidance from national immunization authorities, recognized public-health agencies, regulatory documents, peer-reviewed evidence, and local epidemiological surveillance because recommendations and product availability can change.

Conclusion: Improving Protection Through Coordinated Implementation

PPSV23 remains an important component of pneumococcal disease prevention for selected adults and high-risk populations when used according to applicable clinical guidance. Its public-health value depends on more than vaccine availability: accurate eligibility assessment, appropriate sequencing, reliable delivery, informed acceptance, and sustained monitoring are all essential. Coordinated action across health systems, community providers, digital infrastructure, and procurement networks can help close immunization gaps while preserving patient safety and policy consistency.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. 23-Valent Pneumococcal Polysaccharide Vaccine Market, by Product Type
7.1. Introduction
7.2. Branded Vaccine
7.3. Generic Vaccine
8. 23-Valent Pneumococcal Polysaccharide Vaccine Market, by Formulation
8.1. Introduction
8.2. Auto-disable Prefilled Syringe
8.3. Multi Dose Vial
8.4. Single Dose Glass Vial
8.5. Single Dose Prefilled Syringe
9. 23-Valent Pneumococcal Polysaccharide Vaccine Market, by Route Of Administration
9.1. Introduction
9.2. Intramuscular Injection
9.3. Subcutaneous Injection
10. 23-Valent Pneumococcal Polysaccharide Vaccine Market, by Packaging
10.1. Introduction
10.2. Multi-Dose Packaging
10.3. Single-Dose Packaging
10.4. Unit Dose Packs
11. 23-Valent Pneumococcal Polysaccharide Vaccine Market, by Risk Group
11.1. Introduction
11.2. Chronic Disease Patients
11.2.1. Chronic Heart Disease
11.2.2. Chronic Lung Disease
11.2.3. Diabetes Mellitus
11.2.4. Kidney Disease
11.2.5. Liver Disease
11.3. Elderly Population
11.4. Healthcare Workers
11.5. Immunocompromised Individuals
11.5.1. Asplenic Individuals
11.5.2. Cancer & Chemotherapy Patients
11.5.3. HIV Patients
11.5.4. Organ Transplant Recipients
11.6. Smokers
11.7. Travelers
12. 23-Valent Pneumococcal Polysaccharide Vaccine Market, by End User
12.1. Introduction
12.2. Ambulatory Care Centers
12.3. Clinics
12.3.1. Primary Care Clinics
12.3.2. Specialty Clinics
12.4. Homecare Settings
12.5. Hospitals
12.5.1. Government Hospitals
12.5.2. Private Hospitals
12.6. Research Institutes
12.7. Vaccination Centers
13. 23-Valent Pneumococcal Polysaccharide Vaccine Market, by Sales Channel
13.1. Introduction
13.2. Offline
13.3. Online
14. 23-Valent Pneumococcal Polysaccharide Vaccine Market, by Region
14.1. Introduction
14.2. Asia-Pacific
14.3. Europe
14.4. North America
14.5. Africa
14.6. Latin America
14.7. Middle East
15. 23-Valent Pneumococcal Polysaccharide Vaccine Market, by Group
15.1. Introduction
15.2. NATO
15.3. G7
15.4. European Union
15.5. BRICS
15.6. ASEAN
15.7. GCC
16. 23-Valent Pneumococcal Polysaccharide Vaccine Market, by Country
16.1. Introduction
16.2. United States
16.3. China
16.4. Germany
16.5. Japan
16.6. India
16.7. United Kingdom
16.8. France
16.9. Canada
16.10. Australia
16.11. Italy
16.12. South Korea
16.13. Russia
16.14. Brazil
16.15. Mexico
16.16. Spain
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. Market Concentration Analysis, 2025
17.2.1. Concentration Ratio (CR)
17.2.2. Herfindahl Hirschman Index (HHI)
17.3. Recent Developments & Impact Analysis, 2025
17.4. Product Portfolio Analysis, 2025
17.5. Benchmarking Analysis, 2025
18. Company Profiles
18.1. Beijing Minhai Biotechnology Co Ltd.
18.2. Bharat Biotech International Ltd
18.3. Biological E Limited
18.4. Chengdu Institute of Biological Products Co Ltd.
18.5. Chongqing Zhifei Biological Products Co Ltd.
18.6. CSL Ltd.
18.7. Dr Reddys Laboratories Limited
18.8. Lanzhou Institute of Biological Products Co Ltd.
18.9. Lupin Ltd.
18.10. Mankind Pharma Ltd.
18.11. Merck Sharp & Dohme LLC
18.12. Novavax Inc.
18.13. Panacea Biotec Ltd
18.14. Sanofi Pasteur SA
18.15. Serum Institute of India Pvt Ltd
18.16. Shanghai Institute of Biological Products Co Ltd.
18.17. Sinopharm Group Co Ltd.
18.18. Sinovac Biotech Ltd.
18.19. SK Bioscience Co Ltd.
18.20. Yuxi Walvax Biotechnology Co Ltd.
19. Key Experts
LIST OF FIGURES
FIGURE 1. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market, Years Considered for the Study
FIGURE 2. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market, Research Design
FIGURE 3. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market, Research Framework
FIGURE 4. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market, Data Triangulation
FIGURE 5. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, 2017-2032 (USD Million)
FIGURE 6. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Formulation, 2025 vs 2032 (%)
FIGURE 9. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Formulation, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 11. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Packaging, 2025 vs 2032 (%)
FIGURE 13. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Packaging, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Risk Group, 2025 vs 2032 (%)
FIGURE 15. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Risk Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by End User, 2025 vs 2032 (%)
FIGURE 17. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Sales Channel, 2025 vs 2032 (%)
FIGURE 19. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Sales Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Region, 2025 vs 2032 (%)
FIGURE 21. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 22. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Country, 2025 vs 2032 (%)
FIGURE 24. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 25. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Segmentation & Coverage
TABLE 2. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, 2017-2032 (USD Million)
TABLE 3. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global Branded Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Branded Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Branded Vaccine Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Generic Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Generic Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Generic Vaccine Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 11. Global Auto-disable Prefilled Syringe Market Size, by Region, 2017-2032 (USD Million)
TABLE 12. Global Auto-disable Prefilled Syringe Market Size, by Group, 2017-2032 (USD Million)
TABLE 13. Global Auto-disable Prefilled Syringe Market Size, by Country, 2017-2032 (USD Million)
TABLE 14. Global Multi Dose Vial Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Multi Dose Vial Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Multi Dose Vial Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Single Dose Glass Vial Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Single Dose Glass Vial Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Single Dose Glass Vial Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Single Dose Prefilled Syringe Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Single Dose Prefilled Syringe Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Single Dose Prefilled Syringe Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 24. Global Intramuscular Injection Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global Intramuscular Injection Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global Intramuscular Injection Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Subcutaneous Injection Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Subcutaneous Injection Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Subcutaneous Injection Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Packaging, 2017-2032 (USD Million)
TABLE 31. Global Multi-Dose Packaging Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Multi-Dose Packaging Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Multi-Dose Packaging Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Single-Dose Packaging Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Single-Dose Packaging Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Single-Dose Packaging Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Unit Dose Packs Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Unit Dose Packs Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Unit Dose Packs Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Risk Group, 2017-2032 (USD Million)
TABLE 41. Global Chronic Disease Patients Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Chronic Disease Patients Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Chronic Disease Patients Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Chronic Heart Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Chronic Heart Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Chronic Heart Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Chronic Lung Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Chronic Lung Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Chronic Lung Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Diabetes Mellitus Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Diabetes Mellitus Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Diabetes Mellitus Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Kidney Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Kidney Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Kidney Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Liver Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Liver Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Liver Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Elderly Population Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Elderly Population Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Elderly Population Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Healthcare Workers Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Healthcare Workers Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Healthcare Workers Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Immunocompromised Individuals Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Immunocompromised Individuals Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Immunocompromised Individuals Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Asplenic Individuals Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Asplenic Individuals Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Asplenic Individuals Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global Cancer & Chemotherapy Patients Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Global Cancer & Chemotherapy Patients Market Size, by Group, 2017-2032 (USD Million)
TABLE 73. Global Cancer & Chemotherapy Patients Market Size, by Country, 2017-2032 (USD Million)
TABLE 74. Global HIV Patients Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Global HIV Patients Market Size, by Group, 2017-2032 (USD Million)
TABLE 76. Global HIV Patients Market Size, by Country, 2017-2032 (USD Million)
TABLE 77. Global Organ Transplant Recipients Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. Global Organ Transplant Recipients Market Size, by Group, 2017-2032 (USD Million)
TABLE 79. Global Organ Transplant Recipients Market Size, by Country, 2017-2032 (USD Million)
TABLE 80. Global Smokers Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. Global Smokers Market Size, by Group, 2017-2032 (USD Million)
TABLE 82. Global Smokers Market Size, by Country, 2017-2032 (USD Million)
TABLE 83. Global Travelers Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. Global Travelers Market Size, by Group, 2017-2032 (USD Million)
TABLE 85. Global Travelers Market Size, by Country, 2017-2032 (USD Million)
TABLE 86. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 87. Global Ambulatory Care Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 88. Global Ambulatory Care Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 89. Global Ambulatory Care Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 90. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 92. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 93. Global Primary Care Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. Global Primary Care Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 95. Global Primary Care Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 96. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 97. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 98. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 99. Global Homecare Settings Market Size, by Region, 2017-2032 (USD Million)
TABLE 100. Global Homecare Settings Market Size, by Group, 2017-2032 (USD Million)
TABLE 101. Global Homecare Settings Market Size, by Country, 2017-2032 (USD Million)
TABLE 102. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 103. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 104. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 105. Global Government Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 106. Global Government Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 107. Global Government Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 108. Global Private Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 109. Global Private Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 110. Global Private Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 111. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 112. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 113. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 114. Global Vaccination Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 115. Global Vaccination Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 116. Global Vaccination Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 117. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Sales Channel, 2017-2032 (USD Million)
TABLE 118. Global Offline Market Size, by Region, 2017-2032 (USD Million)
TABLE 119. Global Offline Market Size, by Group, 2017-2032 (USD Million)
TABLE 120. Global Offline Market Size, by Country, 2017-2032 (USD Million)
TABLE 121. Global Online Market Size, by Region, 2017-2032 (USD Million)
TABLE 122. Global Online Market Size, by Group, 2017-2032 (USD Million)
TABLE 123. Global Online Market Size, by Country, 2017-2032 (USD Million)
TABLE 124. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 125. Asia-Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 126. Asia-Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 127. Asia-Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 128. Asia-Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 129. Asia-Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Packaging, 2017-2032 (USD Million)
TABLE 130. Asia-Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Risk Group, 2017-2032 (USD Million)
TABLE 131. Asia-Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Chronic Disease Patients, 2017-2032 (USD Million)
TABLE 132. Asia-Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Immunocompromised Individuals, 2017-2032 (USD Million)
TABLE 133. Asia-Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 134. Asia-Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 135. Asia-Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 136. Asia-Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Sales Channel, 2017-2032 (USD Million)
TABLE 137. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 138. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 139. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 140. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 141. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Packaging, 2017-2032 (USD Million)
TABLE 142. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Risk Group, 2017-2032 (USD Million)
TABLE 143. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Chronic Disease Patients, 2017-2032 (USD Million)
TABLE 144. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Immunocompromised Individuals, 2017-2032 (USD Million)
TABLE 145. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 146. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 147. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 148. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Sales Channel, 2017-2032 (USD Million)
TABLE 149. North America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 150. North America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 151. North America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 152. North America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 153. North America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Packaging, 2017-2032 (USD Million)
TABLE 154. North America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Risk Group, 2017-2032 (USD Million)
TABLE 155. North America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Chronic Disease Patients, 2017-2032 (USD Million)
TABLE 156. North America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Immunocompromised Individuals, 2017-2032 (USD Million)
TABLE 157. North America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 158. North America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 159. North America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 160. North America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Sales Channel, 2017-2032 (USD Million)
TABLE 161. Africa 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 162. Africa 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 163. Africa 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 164. Africa 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 165. Africa 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Packaging, 2017-2032 (USD Million)
TABLE 166. Africa 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Risk Group, 2017-2032 (USD Million)
TABLE 167. Africa 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Chronic Disease Patients, 2017-2032 (USD Million)
TABLE 168. Africa 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Immunocompromised Individuals, 2017-2032 (USD Million)
TABLE 169. Africa 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 170. Africa 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 171. Africa 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 172. Africa 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Sales Channel, 2017-2032 (USD Million)
TABLE 173. Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 174. Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 175. Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 176. Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 177. Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Packaging, 2017-2032 (USD Million)
TABLE 178. Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Risk Group, 2017-2032 (USD Million)
TABLE 179. Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Chronic Disease Patients, 2017-2032 (USD Million)
TABLE 180. Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Immunocompromised Individuals, 2017-2032 (USD Million)
TABLE 181. Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 182. Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 183. Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 184. Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Sales Channel, 2017-2032 (USD Million)
TABLE 185. Middle East 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 186. Middle East 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 187. Middle East 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 188. Middle East 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 189. Middle East 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Packaging, 2017-2032 (USD Million)
TABLE 190. Middle East 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Risk Group, 2017-2032 (USD Million)
TABLE 191. Middle East 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Chronic Disease Patients, 2017-2032 (USD Million)
TABLE 192. Middle East 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Immunocompromised Individuals, 2017-2032 (USD Million)
TABLE 193. Middle East 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 194. Middle East 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 195. Middle East 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 196. Middle East 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Sales Channel, 2017-2032 (USD Million)
TABLE 197. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 198. NATO 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 199. NATO 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 200. NATO 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 201. NATO 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 202. NATO 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Packaging, 2017-2032 (USD Million)
TABLE 203. NATO 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Risk Group, 2017-2032 (USD Million)
TABLE 204. NATO 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Chronic Disease Patients, 2017-2032 (USD Million)
TABLE 205. NATO 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Immunocompromised Individuals, 2017-2032 (USD Million)
TABLE 206. NATO 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 207. NATO 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 208. NATO 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 209. NATO 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Sales Channel, 2017-2032 (USD Million)
TABLE 210. G7 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 211. G7 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 212. G7 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 213. G7 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 214. G7 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Packaging, 2017-2032 (USD Million)
TABLE 215. G7 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Risk Group, 2017-2032 (USD Million)
TABLE 216. G7 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Chronic Disease Patients, 2017-2032 (USD Million)
TABLE 217. G7 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Immunocompromised Individuals, 2017-2032 (USD Million)
TABLE 218. G7 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 219. G7 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 220. G7 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 221. G7 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Sales Channel, 2017-2032 (USD Million)
TABLE 222. European Union 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 223. European Union 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 224. European Union 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 225. European Union 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 226. European Union 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Packaging, 2017-2032 (USD Million)
TABLE 227. European Union 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Risk Group, 2017-2032 (USD Million)
TABLE 228. European Union 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Chronic Disease Patients, 2017-2032 (USD Million)
TABLE 229. European Union 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Immunocompromised Individuals, 2017-2032 (USD Million)
TABLE 230. European Union 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 231. European Union 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 232. European Union 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 233. European Union 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Sales Channel, 2017-2032 (USD Million)
TABLE 234. BRICS 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 235. BRICS 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 236. BRICS 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 237. BRICS 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 238. BRICS 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Packaging, 2017-2032 (USD Million)
TABLE 239. BRICS 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Risk Group, 2017-2032 (USD Million)
TABLE 240. BRICS 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Chronic Disease Patients, 2017-2032 (USD Million)
TABLE 241. BRICS 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Immunocompromised Individuals, 2017-2032 (USD Million)
TABLE 242. BRICS 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 243. BRICS 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 244. BRICS 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 245. BRICS 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Sales Channel, 2017-2032 (USD Million)
TABLE 246. ASEAN 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 247. ASEAN 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 248. ASEAN 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 249. ASEAN 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 250. ASEAN 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Packaging, 2017-2032 (USD Million)
TABLE 251. ASEAN 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Risk Group, 2017-2032 (USD Million)
TABLE 252. ASEAN 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Chronic Disease Patients, 2017-2032 (USD Million)
TABLE 253. ASEAN 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Immunocompromised Individuals, 2017-2032 (USD Million)
TABLE 254. ASEAN 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 255. ASEAN 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 256. ASEAN 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 257. ASEAN 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Sales Channel, 2017-2032 (USD Million)
TABLE 258. GCC 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 259. GCC 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 260. GCC 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 261. GCC 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 262. GCC 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Packaging, 2017-2032 (USD Million)
TABLE 263. GCC 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Risk Group, 2017-2032 (USD Million)
TABLE 264. GCC 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Chronic Disease Patients, 2017-2032 (USD Million)
TABLE 265. GCC 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Immunocompromised Individuals, 2017-2032 (USD Million)
TABLE 266. GCC 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 267. GCC 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 268. GCC 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 269. GCC 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Sales Channel, 2017-2032 (USD Million)
TABLE 270. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Country, 2017-2032 (USD Million)
TABLE 271. United States 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, 2017-2032 (USD Million)
TABLE 272. United States 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 273. United States 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 274. United States 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 275. United States 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Packaging, 2017-2032 (USD Million)
TABLE 276. United States 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Risk Group, 2017-2032 (USD Million)
TABLE 277. United States 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Chronic Disease Patients, 2017-2032 (USD Million)
TABLE 278. United States 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Immunocompromised Individuals, 2017-2032 (USD Million)
TABLE 279. United States 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 280. United States 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 281. United States 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 282. United States 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Sales Channel, 2017-2032 (USD Million)
TABLE 283. China 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, 2017-2032 (USD Million)
TABLE 284. China 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 285. China 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 286. China 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 287. China 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Packaging, 2017-2032 (USD Million)
TABLE 288. China 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Risk Group, 2017-2032 (USD Million)
TABLE 289. China 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Chronic Disease Patients, 2017-2032 (USD Million)
TABLE 290. China 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Immunocompromised Individuals, 2017-2032 (USD Million)
TABLE 291. China 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 292. China 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 293. China 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 294. China 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Sales Channel, 2017-2032 (USD Million)
TABLE 295. Germany 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, 2017-2032 (USD Million)
TABLE 296. Germany 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 297. Germany 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 298. Germany 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 299. Germany 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Packaging, 2017-2032 (USD Million)
TABLE 300. Germany 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Risk Group, 2017-2032 (USD Million)
TABLE 301. Germany 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Chronic Disease Patients, 2017-2032 (USD Million)
TABLE 302. Germany 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Immunocompromised Individuals, 2017-2032 (USD Million)
TABLE 303. Germany 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 304. Germany 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 305. Germany 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 306. Germany 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Sales Channel, 2017-2032 (USD Million)
TABLE 307.

Companies Mentioned

  • Beijing Minhai Biotechnology Co Ltd.
  • Bharat Biotech International Ltd
  • Biological E Limited
  • Chengdu Institute of Biological Products Co Ltd.
  • Chongqing Zhifei Biological Products Co Ltd.
  • CSL Ltd.
  • Dr Reddys Laboratories Limited
  • Lanzhou Institute of Biological Products Co Ltd.
  • Lupin Ltd.
  • Mankind Pharma Ltd.
  • Merck Sharp & Dohme LLC
  • Novavax Inc.
  • Panacea Biotec Ltd
  • Sanofi Pasteur SA
  • Serum Institute of India Pvt Ltd
  • Shanghai Institute of Biological Products Co Ltd.
  • Sinopharm Group Co Ltd.
  • Sinovac Biotech Ltd.
  • SK Bioscience Co Ltd.
  • Yuxi Walvax Biotechnology Co Ltd.

Related Topics

Related Reports

23 Valent Pneumococcal Polysaccharide Vaccine Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030 - Product Image

23 Valent Pneumococcal Polysaccharide Vaccine Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030

  • Report
  • 255 Pages
  • Global
From
23-Valent Pneumococcal Polysaccharide Vaccine Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

23-Valent Pneumococcal Polysaccharide Vaccine Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 73 Pages
  • Global
From
Pneumococcal Vaccine Market - Global Forecast 2026-2032 - Product Image

Pneumococcal Vaccine Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From
Africa 23 Valent Pneumococcal Polysaccharide Vaccine Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2030 - Product Image

Africa 23 Valent Pneumococcal Polysaccharide Vaccine Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2030

  • Report
  • 100 Pages
  • Africa
From
Russia 23 Valent Pneumococcal Polysaccharide Vaccine Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2030 - Product Image

Russia 23 Valent Pneumococcal Polysaccharide Vaccine Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2030

  • Report
  • 80 Pages
  • Russia
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.